EPS: As of FY2025 Q2, the actual value is USD -1.13, missing the estimate of USD -1.0871.EBIT: As of FY2025 Q2, the actual value is USD -73.17 M, missing the estimate of USD -69.22 M.<h3>Segment Revenue</h3><ul><li>Total Operating Expenses: $73.165 million for the three months ended June 30, 2025, compared to $44.122 million for the same period in 2024, representing an increase of $29.043 million.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: $66.096 million for the three months ended June 30, 2025, compared to $33.816 million for the same period in 2024, an increase of $32.280 million.</li><li>Research and Development Expenses: $55.703 million for the three months ended June 30, 2025, compared to $33.206 million for the same period in 2024, an increase of $22.497 million.</li><li>General and Administrative Expenses: $17.462 million for the three months ended June 30, 2025, compared to $10.916 million for the same period in 2024, an increase of $6.546 million.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $110.506 million for the six months ended June 30, 2025, compared to $60.936 million for the same period in 2024.</li><li>Net Cash Provided by Investing Activities: $91.107 million for the six months ended June 30, 2025, compared to net cash used of $200.451 million for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $1.802 million for the six months ended June 30, 2025, compared to $450.370 million for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Accumulated Deficit: $427.351 million as of June 30, 2025, compared to $305.916 million as of December 31, 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Apogee Therapeutics, Inc. plans to advance its programs, including APG777, APG279, APG777 + APG333, APG990, APG333, and APG808, into and through clinical trials and regulatory approval prior to commercialization. The company expects to incur increased expenses as it continues research and development and preclinical development of its other programs.</li><li>Non-Core Business: The company may seek additional collaborations and licensing arrangements to enhance its capabilities and expand its development pipeline.</li><li>Priority: The company estimates that its existing cash and cash equivalents, marketable securities, and long-term marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2028.</li></ul>

Apogee Therapeutic | 10-Q: FY2025 Q2 EPS Misses Estimate at USD -1.13